News

Verge Genomics has announced a three-year partnership with Eli Lilly and Company to discover and develop novel therapies for amyotrophic lateral sclerosis (ALS), a motor neuron disease. As

The US Food and Drug Administration (FDA) has accepted the biologics licence application (BLA) and granted priority review for tezepelumab, which is being developed by AstraZeneca and Amgen,

Altesa Biosciences has signed an exclusive worldwide license agreement with biotechnology firm Vaxart for the development and commercialisation of the latter’s patented formulation of the capsid-binding Vapendavir antiviral.

Eureka Therapeutics and Memorial Sloan Kettering Cancer Center (MSK) have signed a new G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) license agreement with Sanofi to

The European Commission has cleared AstraZeneca’s proposed acquisition of Alexion Pharmaceuticals for $39bn. This marks an ‘important step’ towards the completion of the acquisition, which was first announced

The Russian Direct Investment Fund (RDIF) has announced the production of a test batch of the Russian Covid-19 vaccine, Sputnik V, in Mexico. With this production, Mexico has

GlaxoSmithKline (GSK) and Alector have partnered to co-develop and commercialise two clinical stage monoclonal antibodies for neurodegenerative diseases. Under the deal, the companies will co-develop AL001 and AL101

Seres Therapeutics and Nestlé Health Science have signed an agreement to jointly commercialise SER-109, an investigational oral microbiome therapy, in the US and Canada. SER-109 has been developed

Philip Morris International has signed an agreement to acquire Fertin Pharma from private equity firm EQT for approximately $812.8m (DKK5.1bn). Denmark-based Fertin Pharma is a specialist contract development